Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~Clinical diagnosis of symptomatic acute VVC~3 or more episodes of acute VVC in the past 12 months~Positive KOH~Minimum composite vulvovaginal signs and symptoms score of ≥3 at Screening~Composite vulvovaginal signs and symptoms score of \<3 at Baseline~Must be able to swallow tablets~Key Exclusion Criteria:~Evidence of major organ system disease~Presence or a history of another vaginal or vulvar condition(s)~History of cervical cancer~Poorly controlled diabetes mellitus~Pregnant~Recent use of topical or systemic antifungal drugs~Recent use of immunosuppressive or system corticosteroid therapies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VT-1161 Low-dose 3-month (Type: EXPERIMENTAL): 1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
- VT-1161 Low-dose 6-month (Type: EXPERIMENTAL): 1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
- VT-1161 High-dose 3-month (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
- VT-1161 High-dose 24-week (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 2 placebo tablets once daily for 7 days, then once weekly for 23 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).